Soft-tissue sarcomas

While the exact mechanism of action remains unclear, dacarbazine appears to inhibit DNA, RNA, and protein synthesis. Dacarbazine disappears rapidly from the plasma, with a terminal half-life of about 40 minutes. Dacarbazine has shown clinical benefit in the treatment of melanoma, Hodgkin s lymphoma, and soft tissue sarcomas. Side effects include myelosuppression, severe nausea and vomiting, and a flulike syndrome that starts about 7 days after treatment and lasts 1 to 3 weeks. [Pg.1290]

Vincristine (VCR, Oncovin) ALL HD NHL multiple myeloma breast cancer SCLC, KS brain tumors soft tissue sarcomas osteosarcomas neuroblastoma Wilms tumor... [Pg.1409]

Jin L, Majerus J, Oliveira A, et al. Detection of fusion gene transcripts in fresh-frozen and formalin-fixed paraffin-embedded tissue sections of soft-tissue sarcomas after laser capture microdissection and RT-PCR. Diagn. Mol. Pathol. 2003 12 224-230. [Pg.70]

Data from Hardell, L. 1983. Epidemiological studies on soft-tissue sarcoma, malignant lymphoma, nasal and nasopharyngeal cancer, and their relation to phenoxy acid or chlo-rophenol exposure. Pages 367-374 in G. Choudhary, L.H. Keith, and C. Rappe (eds.). Chlorinated Dioxins and Dibenzofurans in the Total Environment. Butterworth, Woburn, MA. [Pg.1025]

The DNA minor groove binder brostallicin (PNU-166196, 24), currently in Phase 2 clinical trials for the treatment of soft-tissue sarcoma, exhibited potent... [Pg.323]

Abe S, Tokizaki T, Miki Y, Tateishi A, Ogawa K, Nakano H, Matsushita T (2005) Hyperthermic isolated regional perfusion with CDDP for bone and soft-tissue sarcoma of the lower limb pharmacokinetics, thermal dose, toxicity, and feasibility. Cancer Chemotherapy and Pharmacology 56 55-62. [Pg.257]

The results of an antitumor screen are summarized in Table 8.1. The attrition table summarizes the results from 338,072 samples tested against tumor cells derived from soft tissue sarcomas. Given that the samples included one combinatorial collection with approximately 1.5 million compounds and that each natural product extract most likely contained 100 or more, the total number of compounds tested in this screen exceeded 5 million. As shown in the first column of Table 8.1, the samples were from 11 collections composed of single synthetics, compounds synthesized by combinatorial chemistries, and purified natural products and extracts. The natural products were derived from microorganisms (actinomyces and fungi), plants, and marine invertebrates. [Pg.156]

As might be expected from a screen in which the target tumor was a soft tissue sarcoma, those tumors were among the most sensitive to the compound, along with ovarian tumors, mesotheliomas, melanomas, and lung carcinomas. Tumors least sensitive to this compound included pancreatic carcinomas, neuroblastomas, and especially, renal cell carcinomas. As a rule, for the seven classes of compounds identified in the screen, soft tissue sarcomas, ovarian carcinomas, and mesotheliomas were the most sensitive tumor types. [Pg.158]

Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL(R)/CAELYX(R)) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma, a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001 37 870. [Pg.47]

Swanson, P. E. (1991) Heffalumps, jaguars, and Cheshire cats a commentary on cytokeratins and soft tissue sarcomas. Am. J. Clin. Pathol. 95(suppl. 1), S2-S7. [Pg.434]

Trabectedin is licensed for the treatment of advanced soft-tissue sarcoma when treatment with anthracyclines and ifosfamide has failed or is contraindicated. It is administered by intravenous infusion. Trabectedin may cause hepatobiliary disorders and for this reason hepatic function should be evaluated before starting treatment and during treatment. Dexamethasone is administered intravenously with trabectedin for its anti-emetic and hepatoprotective effects. As with other antineoplastic drugs, trabectedin causes nausea and vomiting and bone-marrow suppression as side-effects. [Pg.156]

Trabectedin (36 Yondelis, ecteinascidin-743, ET-743 Zelfia and Johnson and Johnson, 2007), a tetrahydroisoquinoline alkaloid produced hy the ascidian Ecteinascidia turbinate,received approval for its sale in Europe, Russia and South Korea by Zelfia and Johnson and Johnson under the brand name YondelisT for the treatment of advanced soft tissue sarcoma (STS). Trabectedin (36) binds to the minor groove of DNA and inhibits cell proliferation by disrupting the cell cycle. [Pg.42]

In September 2007, the EMEA approved the use of trabectidin against ovarian cancer (OC) and STS. In November 2009, Yondelis received its second marketing authorization from the European Commission for its administration in combination with pegylated liposomal doxorubicin (Doxil, Caelyx) for the treatment of women with relapsed ovarian cancer presently, trabectedin (36) is under Phase II trials for the treatment of paediatric sarcomas as well as breast and prostate cancers. The European Commission and the US Food and Drug Administration (FDA) have granted orphan drug status to trabectedin for soft tissue sarcomas and... [Pg.42]

Schmitt T, Keller E, Dietrich S, Wuchter P, Ho AD, Egerer G (2010) Trabectedin for metastatic soft tissue sarcoma A retrospective single center analysis. Mar Drugs 8 2647-2658. [Pg.143]

Carter NJ, Keam SJ. (2007) Trabectedin A review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 67 2257-2276. [Pg.143]

Daunomycin Soft-tissue sarcomas, Mammalian carcinoma, Hepatoma... [Pg.214]

Tasonermin - recombinant TNF Soft tissue sarcoma of the limbs... [Pg.60]

D and 2,4,5-T). A subsequent mortality study of these veterans did find an elevated standardized proportionate mortality ratio for soft tissue sarcoma, but it was not based on adequate numbers of deaths or adequate exposure data. ... [Pg.234]

Hardell L, Eriksson M The association between soft-tissue sarcomas and exposure to phenoxyacetic acids. A new case-referent study. Cancer 61-.652-656, 1988... [Pg.235]

Hoar SK, Blair A, Holmes FF, et al Agricultural herbicide use and risk of lymphoma and soft-tissue sarcoma. JAMA 256 1141-1147, 1986... [Pg.235]

Johnson ES Review. Association between soft-tissue sarcomas, malignant lymphomas, and phenoxy herbicides/chlorophenols evidence from occupational cohort studies. Fundam Appl Toxicol 14 219-234, 1990... [Pg.235]

Wiklund K, Holme L Soft-tissue sarcoma risk in Swedish agricultural and forestry workers. J Natl Cancer Inst 76 229-234, 1986... [Pg.235]

Kang HK et al Soft-tissue sarcomas and military service in Vietnam A case comparison group analysis of hospital patients. J Occup... [Pg.235]

Kogan MD, Clapp RW Soft-tissue sarcoma mortality among Vietnam veterans in Massachusetts, 1972-1983. Int J Epidemiol 17 39-43, 1988... [Pg.235]

Case reports and case control studies in humans have suggested a possible association between cancer, including soft tissue sarcoma, acute leukemia, Hodgkin disease, and non-Hodgkin lymphoma, and occupational exposure to pentachlorophenol. However, in all cases concomitant exposure to other toxic substances may have contributed to the effects seen. "... [Pg.560]

Several epidemiological studies in Sweden suggested an association between exposure to phenoxyherbicides (and/or their contaminants) and soft tissue sarcomas." There has also been widespread concern among Vietnam veterans that exposure to the defoliant Agent Orange, which contains equal quantities of 2,4-D and... [Pg.702]

Doxorubicin 1974 Osteogenic sarcoma, Hodgkin s disease, CML, soft tissue sarcoma Inhibitor of DNA replication, transcription, repair [20]... [Pg.5]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...